GAIN for loss: adalimumab for infliximab-refractory Crohn disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

1. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Therapeutic advances in gastroenterology · 2017
   Article
2. Adalimumab for the treatment of Crohn's disease.Biologics : targets & therapy · 2008
   Article

Corrections and comments

• Comment on
  Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.2007

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as